NASDAQ · SPPI
Healthcare · Biotechnology
$1.03
Down-$0.01 (-0.49%)
Updated Aug 28, 2026, 6:26 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
SPPI does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning SPPI.
SPPI research
Company profile and research snapshot.
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is based in Boston, Massachusetts.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 26, 2023 | HC Wainwright & Co. | Neutral | — |
| May 15, 2023 | Jefferies | Hold | — |
| Apr 26, 2023 | HC Wainwright & Co. | Neutral | — |
| Apr 26, 2023 | JMP Securities | Market Perform | — |
| Feb 6, 2023 | JMP Securities | Market Outperform | — |
No generated briefing is available yet.
globenewswire.com · Nov 17, 2025
Artisan and Tulex Report Positive Phase 2a Results for Autism Drug ART-501 Artisan and Tulex Report Positive Phase 2a Results for Autism Drug ART-501
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SPPI.
No results
No recent SID articles mention SPPI.
